Here, we present a method to evaluate the impact of CYP3A4, COMT V158M, and OPRM1 A118G polymorphisms on sufentanil efficacy and maternal outcomes during labor analgesia, enabling pharmacogenetic analysis to guide personalized pain management.
A subscription to JoVE is required to view this content. Sign in or start your free trial.
Research Article
* These authors contributed equally
Here, we present a method to evaluate the impact of CYP3A4, COMT V158M, and OPRM1 A118G polymorphisms on sufentanil efficacy and maternal outcomes during labor analgesia, enabling pharmacogenetic analysis to guide personalized pain management.
Genetic polymorphisms in CYP3A4, COMT V158M, and OPRM A118G may influence analgesic response, hemodynamic regulation, and postpartum recovery, while parity is thought to affect labor outcomes and adverse events. This study investigated how these genotypes and parity impact maternal and neonatal outcomes, labor duration, pain control, and postpartum complications in 380 pregnant women stratified by genotype. Data on baseline characteristics, labor duration, VAS pain scores, and postpartum adverse events were collected, and safety indicators such as blood pressure, heart rate, fetal outcomes, and Apgar scores were analyzed. Associations between parity and postpartum responses were explored using univariate and logistic regression models. Baseline variables were largely comparable across genotypes except for a higher BMI in the CYP3A4 CT/TT group. Sufentanil consumption was significantly higher in CYP3A4 CT/TT and OPRM A118G GA/GG carriers, although labor duration did not differ among genotypes. OPRM A118G GA/GG carriers also showed a higher incidence of fever (P = 0.016) and greater reductions in blood pressure after intervention (P < 0.001), though all groups achieved similar pain relief. Multiparas experienced less urinary retention (P = 0.005) but more pruritus (P = 0.011), and logistic regression confirmed smaller decreases in systolic blood pressure (OR = 1.049, P = 0.001) and lower risk of pruritus (OR = 0.326, P = 0.01) in this group. Although CYP3A4, COMT, and OPRM A118G genotypes did not broadly influence maternal or neonatal outcomes, carriers of CYP3A4 CT/TT and OPRM A118G GA/GG required higher sufentanil doses and displayed genotype-specific hemodynamic responses, while parity was associated with distinct adverse event profiles and blood pressure changes. These findings highlight the relevance of genetic polymorphisms and parity in guiding personalized postpartum care.
Labor pain ranks among the most severe forms of pain a woman can experience. Effective pain management is crucial, not only for comfort but also to reduce associated stress and psychological distress1,2. Inadequate control of labor pain may trigger shifts in maternal hormones, such as catecholamines and endorphins, which can lower pain thresholds and heighten anxiety about childbirth. This increased pain sensitivity may induce significant adverse emotional reactions in both the mother and fetus, potentially resulting in trauma3,4. Therefore, pain relie....
Access restricted. Please log in or start a trial to view this content.
The reagents and equipment used in this study are listed in the Table of Materials.
1. Study design, setting, and participant selection
This prospective observational study investigated the effects of OPRM1 A118G, COMT V158M, and CYP3A4 genetic polymorphisms on the safety and efficacy of sufentanil for labor analgesia. Participants were recruited from women aged 18-45 years with uncomplicated singleton cephalic pregnancies between 37-42 weeks of gestation, who received labor analgesia at the study institution from September 1, 2020, to December 31, 2023. The study was conducted in ....
Access restricted. Please log in or start a trial to view this content.
General information
A schematic representation of the study framework is presented in Figure 1. A total of 380 eligible participants were identified. The mean (SD) age was 30.49 ± 3.87 years for the CYP3A4 CC group, 30.44 ± 3.68 years for the CYP3A4 CT/TT group, 30.53 ± 3.95 years for the COMT GG group, 30.40 ± 3.62 years for the COMT GA/AA group, 30.70 ± 3.89 years for the OPRM1 A118G AA group, and 30.30 ± 3.73 years for the OPRM1 A118G GA/GG group, with no significant .......
Access restricted. Please log in or start a trial to view this content.
This study aimed to investigate the effects of CYP3A4, COMT V158M, and OPRM genotypes on maternal and infant outcomes, duration of labor, postpartum adverse reactions, and visual analog scale (VAS) pain scores in 380 pregnant women. Key findings indicate that, although demographic factors were generally comparable across groups, women with the CYP3A4 CT/TT genotype had higher pre-pregnancy and prenatal BMI levels than those with the CYP3A4 CC genotype (P = 0.002 and P = 0.021, respectively). Moreover, s.......
Access restricted. Please log in or start a trial to view this content.
The authors have no conflicts of interest to declare.
None.
DATA AVAILABILITY:
All data generated in this study have been fully discussed and presented in Supplementary File 1.
AUTHOR CONTRIBUTION:
Huiqiong Huang, Yunhong Zhang, and Junxiang Jia contributed equally to this work. Huiqiong Huang and Yunhong Zhang were responsible for study design and planning, data collection and entry, as well as literature analysis and research. Junxiang Jia contributed to data collection, statistical analysis, and data interpretation. Zhuanghui Zhu supervised the study, contributed to the study design and data interpret....
Access restricted. Please log in or start a trial to view this content.
| Name | Company | Catalog Number | Comments |
|---|---|---|---|
| 16-Gauge Polyethylene Catheter | Smiths Medical | 504-009 | Used for tracheal intubation in rats |
| 17-Gauge Tuohy Needle | B. Braun | 331090 | Used for epidural puncture at L3-L4 |
| Annexin V-FITC | BD Biosciences | 556547 | Used in apoptosis detection with flow cytometry |
| Capillary Electrophoresis DNA Sequencer | Applied Biosystems | 3730xl | Used to sequence PCR products for genotyping |
| Collagenase Type II | Worthington | LS004176 | 0.2%, for enzymatic digestion of cardiac tissue |
| DNA Extraction Kit | Qiagen | 69504 | Extracts genomic DNA from whole blood samples |
| Flow Cytometer (488 nm) | BD Biosciences | 342940 | Used to detect Annexin V-FITC/PI labeled cells |
| GeneMarker Software | SoftGenetics | GM2024 | Used for SNP analysis and genotype calling |
| Generic Graphing Software | GraphPad | v9.5 | Used for visualization of statistical data |
| Haploview Software | Broad Institute | v4.2 | Used for Hardy-Weinberg equilibrium and LD analysis |
| Infusion Pump | Smiths Medical | CADD-5700 | Used for continuous epidural drug infusion |
| Lidocaine | Not specified | Not specified | 0.8%, 3 ml test dose for epidural test block |
| Nylon Suture (8-0) | Ethicon | W9823 | Used for LAD coronary artery ligation in MIRI model |
| PCEA System | B. Braun | 331090 | Patient-controlled epidural analgesia system |
| PCR Purification Kit | Omega Bio-Tek | D2500-01 | Purifies PCR products before sequencing |
| Pentobarbital Sodium | Merck | 1.46005 | 3% solution, 50 mg/kg for anesthesia of rats |
| Polyethylene Tubing | Becton Dickinson | 431432 | Used to create reversible coronary ligation |
| Propidium Iodide (PI) | Sigma-Aldrich | P4170 | Used at 5 µg/ml for apoptosis detection |
| Protease | Sigma-Aldrich | P5147 | 0.1%, used with collagenase for tissue digestion |
| Ropivacaine | Not specified | Not specified | 0.08% concentration for labor analgesia |
| Statistical Software | IBM SPSS | v29.0 | Used for RM-ANOVA, logistic regression, and PSM |
| Sufentanil | Not specified | Not specified | Used for epidural labor analgesia (0.3 µg/ml) |
| Taq DNA Ligase | New England Biolabs | M0208L | Used in LDR reaction for genotyping |
| Taq DNA Polymerase | Takara | RR001A | Used in PCR amplification for genotyping |
Access restricted. Please log in or start a trial to view this content.
This article has been published
Video Coming Soon